Meshach Asare-Werehene

433 total citations
19 papers, 296 citations indexed

About

Meshach Asare-Werehene is a scholar working on Molecular Biology, Cell Biology and Immunology. According to data from OpenAlex, Meshach Asare-Werehene has authored 19 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Cell Biology and 5 papers in Immunology. Recurrent topics in Meshach Asare-Werehene's work include Extracellular vesicles in disease (7 papers), Caveolin-1 and cellular processes (4 papers) and MicroRNA in disease regulation (3 papers). Meshach Asare-Werehene is often cited by papers focused on Extracellular vesicles in disease (7 papers), Caveolin-1 and cellular processes (4 papers) and MicroRNA in disease regulation (3 papers). Meshach Asare-Werehene collaborates with scholars based in Canada, Japan and Taiwan. Meshach Asare-Werehene's co-authors include Benjamin K. Tsang, Dylan Burger, Anne‐Marie Mes‐Masson, Eurı́dice Carmona, Tien Le, Dar-Bin Shieh, Pei‐Wen Wang, Arkadiy Reunov, Mohammad Reza Abedini and Laudine Communal and has published in prestigious journals such as Cancer Research, Oncogene and Scientific Reports.

In The Last Decade

Meshach Asare-Werehene

15 papers receiving 293 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Meshach Asare-Werehene Canada 11 202 118 68 32 31 19 296
Bangdong Liu China 7 172 0.9× 125 1.1× 43 0.6× 35 1.1× 12 0.4× 10 261
Edyta Vieth United States 7 267 1.3× 113 1.0× 26 0.4× 72 2.3× 9 0.3× 7 328
Yu-Jia Shiah Canada 6 316 1.6× 84 0.7× 41 0.6× 99 3.1× 31 1.0× 6 447
Grete Hasvold Norway 9 193 1.0× 87 0.7× 18 0.3× 101 3.2× 31 1.0× 13 348
Haruko Kunitomi Japan 9 183 0.9× 112 0.9× 16 0.2× 71 2.2× 24 0.8× 17 311
Samir H. Barghout Canada 9 220 1.1× 42 0.4× 15 0.2× 63 2.0× 18 0.6× 20 272
Bowen Wang China 9 250 1.2× 143 1.2× 61 0.9× 22 0.7× 17 0.5× 17 303
Vasudeva Bhat Canada 10 139 0.7× 108 0.9× 22 0.3× 90 2.8× 32 1.0× 26 279

Countries citing papers authored by Meshach Asare-Werehene

Since Specialization
Citations

This map shows the geographic impact of Meshach Asare-Werehene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meshach Asare-Werehene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meshach Asare-Werehene more than expected).

Fields of papers citing papers by Meshach Asare-Werehene

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meshach Asare-Werehene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meshach Asare-Werehene. The network helps show where Meshach Asare-Werehene may publish in the future.

Co-authorship network of co-authors of Meshach Asare-Werehene

This figure shows the co-authorship network connecting the top 25 collaborators of Meshach Asare-Werehene. A scholar is included among the top collaborators of Meshach Asare-Werehene based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meshach Asare-Werehene. Meshach Asare-Werehene is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Asare-Werehene, Meshach, et al.. (2025). The case of a bloody mess – Bictegravir/emtricitabine/tenofovir alafenamide induced colitis. Clinical Biochemistry. 137. 110910–110910.
2.
Yasavoli‐Sharahi, Hamed, et al.. (2025). Global DNA methylation signatures associated with chemoresistance and poor prognosis of high grade serous ovarian cancer. Scientific Reports. 15(1). 36869–36869.
3.
Bohn, Mary Kathryn, Meshach Asare-Werehene, Felix Leung, Davor Brinc, & Rajeevan Selvaratnam. (2024). Discordance between creatinine and cystatin C-based estimation of glomerular filtration rate (eGFR) in solid organ transplant recipients. Clinical Biochemistry. 135. 110853–110853.
4.
Asare-Werehene, Meshach, et al.. (2024). The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance. Journal of Ovarian Research. 17(1). 15–15. 4 indexed citations
5.
6.
Salehi, Reza, Brandon A. Wyse, Meshach Asare-Werehene, et al.. (2023). Androgen-induced exosomal miR-379-5p release determines granulosa cell fate: cellular mechanism involved in polycystic ovaries. Journal of Ovarian Research. 16(1). 74–74. 10 indexed citations
7.
Asare-Werehene, Meshach, Robert Hunter, Arkadiy Reunov, et al.. (2023). The Application of an Extracellular Vesicle-Based Biosensor in Early Diagnosis and Prediction of Chemoresponsiveness in Ovarian Cancer. Cancers. 15(9). 2566–2566. 10 indexed citations
8.
Salehi, Reza, Meshach Asare-Werehene, Brandon A. Wyse, et al.. (2023). Granulosa cell-derived miR-379-5p regulates macrophage polarization in polycystic ovarian syndrome. Frontiers in Immunology. 14(16). 18–1104550. 21 indexed citations
9.
Asare-Werehene, Meshach, Arkadiy Reunov, Dylan Burger, et al.. (2023). Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin. Journal of Ovarian Research. 16(1). 14–14. 7 indexed citations
10.
Asare-Werehene, Meshach, Hideaki Tsuyoshi, Huilin Zhang, et al.. (2022). Plasma Gelsolin Confers Chemoresistance in Ovarian Cancer by Resetting the Relative Abundance and Function of Macrophage Subtypes. Cancers. 14(4). 1039–1039. 16 indexed citations
11.
Asare-Werehene, Meshach, et al.. (2022). Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance. Cells. 11(20). 3305–3305. 11 indexed citations
12.
Asare-Werehene, Meshach, Michaeline McGuinty, Yannick Galipeau, et al.. (2022). Longitudinal profiles of plasma gelsolin, cytokines and antibody expression predict COVID-19 severity and hospitalization outcomes. Frontiers in Immunology. 13. 1011084–1011084. 4 indexed citations
13.
Asare-Werehene, Meshach, et al.. (2021). Determination of chemoresistance in ovarian cancer by simultaneous quantification of exosomes and exosomal cisplatin with surface enhanced Raman scattering. Sensors and Actuators B Chemical. 354. 131237–131237. 14 indexed citations
14.
Yeboah, Helena, et al.. (2021). COVID-19 in Africa: an ovarian victory?. Journal of Ovarian Research. 14(1). 70–70. 6 indexed citations
15.
Asare-Werehene, Meshach, Laudine Communal, Eurı́dice Carmona, et al.. (2020). Plasma Gelsolin Inhibits CD8+ T-cell Function and Regulates Glutathione Production to Confer Chemoresistance in Ovarian Cancer. Cancer Research. 80(18). 3959–3971. 43 indexed citations
16.
Tsuyoshi, Hideaki, Makoto Orisaka, Yūkō Fujita, et al.. (2020). Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer. BMC Cancer. 20(1). 467–467. 17 indexed citations
17.
18.
Asare-Werehene, Meshach, Laudine Communal, Eurı́dice Carmona, et al.. (2019). Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer. Scientific Reports. 9(1). 13924–13924. 16 indexed citations
19.
Asare-Werehene, Meshach, Kiran Nakka, Arkadiy Reunov, et al.. (2019). The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene. 39(7). 1600–1616. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bangdong Liu Breakdown of academic impact, for papers by Edyta Vieth Breakdown of academic impact, for papers by Yu-Jia Shiah Breakdown of academic impact, for papers by Grete Hasvold Breakdown of academic impact, for papers by Haruko Kunitomi Breakdown of academic impact, for papers by Samir H. Barghout Breakdown of academic impact, for papers by Bowen Wang Breakdown of academic impact, for papers by Vasudeva Bhat
Rankless by CCL
2026